Non-metastatic NSCLC and other thoracic malignancies
Invited discussant abstracts 1179PD and 1508PD
Date
10 Oct 2016Session
Non-metastatic NSCLC and other thoracic malignanciesPresenters
Jens SoerensenAuthors
J.B. SoerensenAuthor affiliations
- Department Of Oncology, Rigshospitalet, Copenhagen University Hospital, 2100 - Copenhagen/DK
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
3259 - Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer
Presenter: Patrick Forde
Session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
3823 - Multi-centre randomized controlled study comparing adjuvant vs neo-adjuvant chemotherapy with docetaxel plus carboplatin in resectable stage IB to IIIA NSCLC: final results of CSLC0501
Presenter: Yi-Long Wu
Session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
Invited discussant LBA41 and abstract 1178O
Presenter: Paul Baas
Session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Slides
Webcast
3894 - Randomized phase 2 study of investigational aurora A kinase (AAK) inhibitor alisertib (MLN8237) + paclitaxel (P) vs placebo + P as second line therapy for small-cell lung cancer (SCLC)
Presenter: Taofeek Owonikoko
Session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
4152 - Small cell lung carcinoma harbors targetable alterations including MYCL1 fusions responding to aurora kinase inhibitor
Presenter: Siraj Ali
Session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Invited discussant abstracts 1423O and 1424O
Presenter: Pilar Garrido Lopez
Session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Slides
Webcast
4203 - Low dose CT scan screening versus empiric surveillance in asbestos exposed subjects: Update of ATOM 002 study
Presenter: Gianpiero Fasola
Session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
2337 - Patient-reported outcomes (PROs) and impact of lactate dehydrogenase (LDH) levels on outcomes in a phase 3 trial (NGR015) with best investigator choice (BIC) plus or minus NGR-hTNF in previously treated patients with malignant pleural mesothelioma (MPM)
Presenter: Vanesa Gregorc
Session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
3008 - Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC)
Presenter: Lecia Sequist
Session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
2926 - Phase II study of roniciclib in combination with cisplatin/etoposide or carboplatin/etoposide as first-line therapy in subjects with extensive-disease small cell lung cancer (ED-SCLC)
Presenter: Martin Reck
Session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract